摘要: This chapter summarizes the theoretical background of cancer therapeutics that abrogate cell cycle G2 checkpoint and reviews molecular mechanism s cascade. In addition, screening procedures to identify candidate compounds, currently available compounds in clinical trials with checkpoint-abrogating potential are discussed.